From Seekingalpha · SA Transcripts · · 50s
Capricor Shares HOPE-3 Data Update
Capricor presents HOPE-3 extension results and deramiocel progress for Duchenne muscular dystrophy treatment.
In brief
Capricor presents HOPE-3 extension results and deramiocel progress for Duchenne muscular dystrophy treatment. Capricor Therapeutics shared HOPE-3 open-label extension data and deramiocel updates for Duchenne muscular dystrophy ahead of November PDUFA date. Originally reported by Seekingalpha.
Capricor Webinar Announcement
Capricor Therapeutics hosts webinar to share HOPE-3 open-label extension data and deramiocel updates for Duchenne muscular dystrophy treatment.
Webinar Details
Webinar recorded for public access, with Q&A session planned for end of presentation.
Company Participants
Linda Marbán, Co-Founder, President, CEO & Director leads presentation with Dr. Craig McDonald and Dr. Chet Villa.
HOPE-3 Update
Capricor discusses HOPE-3 2-year open-label extension data and deramiocel progress for Duchenne muscular dystrophy treatment.
PDUFA Timeline
Company shares data ahead of November PDUFA date for regulatory approval timeline.
The main idea
Capricor Therapeutics shared HOPE-3 open-label extension data and deramiocel updates for Duchenne muscular dystrophy ahead of November PDUFA date.
